PROGRESSIVENESS AND GENERALIZABILITY OF THE EFFECTS OF ALENDRONATE ON BONE MASS AND SAFETY EXPERIENCE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

被引：0
|
作者：
EMKEY, R
CORREAROTTER, R
SANTORA, A
LOMBARDI, A
DAIFOTIS, A
机构：
[1] READING MED CTR,BONE RES CTR,W READING,PA 19610
[2] NATL INST NUTR,MEXICO CITY,DF,MEXICO
[3] MERCK & CO INC,MERCK SHARP & DOHME RES LABS,RAHWAY,NJ 07065
来源：
ARTHRITIS AND RHEUMATISM | 1995年 / 38卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1239 / 1239
页数：1
相关论文
共 50 条
  • [21] Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass
    Goldstein, Steven R.
    Bhattoa, Harjit Pal
    Neven, Patrick
    Cox, David A.
    Dowsett, Sherie A.
    Alam, Jahangir
    Sipos, Adrien
    Muram, David
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2012, 19 (01): : 41 - 47
  • [22] Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
    Torring, Ove
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2015, 7 (03) : 88 - 102
  • [23] Using in postmenopausal women with bone mass loss raloxifene and alendronate
    Bazarra, A
    Castro, A
    Suarez, M
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S172 - S172
  • [24] Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis
    Iwamoto, Jun
    Takeda, Tsuyoshi
    Sato, Yoshihiro
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) : 919 - 928
  • [25] Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass
    Recker, Robert R.
    Kendler, David
    Recknor, Christopher P.
    Rooney, Theodore W.
    Lewiecki, E. Michael
    Utian, Wulf H.
    Cauley, Jane A.
    Lorraine, Joanne
    Qu, Yongming
    Kulkarni, Pandurang M.
    Gaich, Carol L.
    Wong, Mayme
    Plouffe, Leo, Jr.
    Stock, John L.
    BONE, 2007, 40 (04) : 843 - 851
  • [26] Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis
    Sanad, Z.
    Ellakwa, H.
    Desouky, B.
    CLIMACTERIC, 2011, 14 (03) : 369 - 377
  • [27] Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women
    Emkey, RD
    Reid, I
    Mulloy, AL
    Correa-Rotter, R
    Favus, M
    Bone, H
    Gupta, J
    LaMotta, A
    Santora, AC
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S32 - S32
  • [28] Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women
    Emkey, RD
    Reid, I
    Mulloy, AL
    Correa-Rotter, R
    Favus, M
    Bone, H
    Gupta, J
    La Motta, A
    Santora, AC
    BONE, 2003, 32 (05) : S206 - S206
  • [29] BONE MARKERS CTX AND OSTEOCALCIN ASSESSMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS ON ALENDRONATE TREATMENT
    Meceska-Jovcevska, J.
    Subeska-Stratrova, S.
    Janicevik-Ivanovska, D.
    Gruev, T.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S434 - S434
  • [30] ALENDRONATE DISCONTINUATION IN POSTMENOPAUSAL WOMEN TREATED FOR OSTEOPOROSIS
    Powell, Diane
    Than, Soe Soe
    Butler, Robin
    Matthews, Clare
    Garton, Mark
    RHEUMATOLOGY, 2014, 53 : 133 - 134
12345